Board of Directors
James N. Wilson
Chairman of the Board
James N. Wilson has served as a Director and as Chairman of our Board since 1999. Since 2005, he has also been the Chairman of the Board of NuGEN Technologies, Inc. (“NuGEN”), a provider of systems for genomic analysis. From 2002 to 2009, Mr Wilson served as the lead independent director of Amylin Pharmaceuticals, Inc. (“Amylin”), a publicly traded biopharmaceutical company, and from 1996 to 2001, he was Chairman of the Board of Amira Medical, Inc., which was acquired by Hoffmann-La Roche A.G. From 1991 to 1994, Mr Wilson was Chief Operating Officer of Syntex Corporation (“Syntex”), which was acquired by Roche Holding, Ltd. From 1989 to 1990, Mr Wilson was Chairman and Chief Executive Officer of Neurex Corporation (“Neurex”), which was acquired by Elan Corporation plc. From 1982 to 1988, he was Chief Executive Officer of LifeScan, Inc., which was acquired by Johnson & Johnson Company. Mr Wilson received his BA and MBA from the University of Arizona. Mr Wilson brings to our Board extensive experience in the biotechnology industry, as both a Chief Executive Officer and Director.
Gregg Alton joined Corcept’s Board in March 2020 after serving twenty years as a senior executive at Gilead Sciences, Inc. From January 2019 until March 2019, Mr. Alton was Gilead’s interim Chief Executive Officer. Prior to that, he was the company’s Chief Patient Officer, responsible for Gilead’s government affairs, public affairs, patient outreach and engagement initiatives, as well as efforts to facilitate access to its medicines around the world. Mr. Alton also oversaw Gilead’s corporate and medical affairs functions, its digital patient solutions and patient-centered outcomes groups, and commercial operations in certain countries. Before that, he was the company’s General Counsel. Prior to joining Gilead, Mr. Alton was an attorney at the law firm of Cooley Godward, LLP, where he specialized in corporate finance transactions for healthcare and information technology companies. Mr. Alton is a member of the Board of Directors of Enochian Biosciences, the AIDS Institute, the Boys and Girls Clubs of Oakland, and the Partners in Health Board of Trustees. Mr. Alton received a bachelor’s degree in legal studies from the University of California at Berkeley and a law degree from Stanford University.
G. Leonard Baker, Jr
G. Leonard Baker, Jr, has served as a member of our Board since 1999. Since 1973, Mr Baker has been a Managing Director of the General Partner of Sutter Hill Ventures, a venture capital firm in Palo Alto, California. Mr Baker currently serves on the boards of a number of private companies. He received his BA from Yale University and his MBA from Stanford University. Mr Baker brings to our Board extensive experience in advising companies about finance, strategic transactions, and operations.
Joseph K. Belanoff
Joseph K. Belanoff, MD, is a Co-founder of our company and has served as a member of our Board and our Chief Executive Officer since 1999, and as our President since 2014. Dr Belanoff is a clinical faculty member at Stanford University (School of Medicine), where he has, since 1992, held various positions in the Department of Psychiatry and Behavioral Sciences. Dr Belanoff received his BA from Amherst College and his MD from Columbia University’s College of Physicians & Surgeons. Dr Belanoff brings to our Board a deep knowledge of our financial activities, commercial operations, and our research and development programs. He also has valuable expertise in business administration, drug discovery, clinical medicine, and psychopharmacology.
Gillian M. Cannon
Gillian M. Cannon, PhD, became a member of our Board in November 2020. Dr. Cannon is currently President of Alyvant and Executive in Residence for Roivant Sciences. Dr. Cannon brings to Corcept more than 30 years of experience in the pharmaceutical industry, where she has served in leadership roles at Merck and Co. Inc., UCB Inc. and Otsuka Pharmaceuticals. In her 27-year career at Merck, Dr. Cannon held a variety of senior positions, including Global Vice President for Commercial Operations at Merck’s start-up biosimilar business, Merck BioVentures; Business Unit Head for Merck’s specialty products franchise; and Global Commercial Head of its neuroscience franchise. Dr. Cannon currently serves as a Board Director for Affibody AB, a Swedish biotechnology company. She holds a Bachelor of Science in biochemistry from the University of Edinburgh, Scotland and a PhD in health administration from the Temple University School of Business.
David L. Mahoney
David L. Mahoney is a private investor who has served as a member of our Board since July 2004. From 1999 to 2001, Mr Mahoney served as Co-Chief Executive Officer of McKesson HBOC, Inc., a healthcare supply management and information technology company, and as Chief Executive Officer of McKesson LLC, a healthcare management and connectivity company. He joined McKesson Corporation in 1990 as Vice President for Strategic Planning. Prior to joining McKesson, Mr Mahoney was a principal with McKinsey & Company, a management consulting firm, where he worked from 1981 to 1990. Mr Mahoney serves on the board of Symantec Corporation (“Symantec”), a publicly traded software technology company, including as chair of its Compensation Committee and a member of its Nominating and Governance Committee; and Adamas Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, where he is the Lead Independent Director and chair of the Compensation Committee. Mr Mahoney also served as a member of the Audit Committee of Symantec from 2003 to 2011. He also serves on the boards of directors of the San Francisco Museum of Modern Art and Mercy Corps and is a Trustee of the Schwab/Laudus Family of Funds and Mount Holyoke College. Mr Mahoney previously served on the board of directors of KQED, Inc., a public nonprofit television and radio operator. Mr Mahoney received his BA from Princeton University and his MBA from Harvard University. Mr Mahoney brings to our Board extensive experience in pharmaceutical management, operating strategy, and logistics.
Kimberly Park became a member of our Board in September 2019. She was Global Vice President of Customer Strategy and Innovation at Merck & Co. from 2014 to 2018 and also held global and US leadership roles at Merck from 1997 to 2005, including U.S. Vice President of Managed Care Marketing. From 2005 to 2014, Ms. Park served in senior leadership roles at Johnson and Johnson, including Founding Partner and Global Vice President of Janssen Healthcare Innovation from 2010 to 2014 and U.S. Vice President of Primary Care Sales and Marketing of Janssen Pharmaceuticals from 2005 to 2010. Prior to joining Merck, Ms. Park held U.S. and global commercial leadership positions at GlaxoSmithKline plc. Ms. Park currently serves on the board of directors of Besser Company, a manufacturer of equipment for the building materials industry, and as a trustee for two private foundations. She is a Mentor for Philadelphia Alliance of Capital and Technology. Ms. Park received her BA in International Business from the University of Michigan.
Daniel N. Swisher, Jr
Daniel N. Swisher, Jr, became a member of our Board in June 2015. He has been the President and Chief Operating Officer of Jazz Pharmaceuticals since January 2018. From 2003 to December 2017, he was Chief Executive Officer and a member of the board of directors of Sunesis Pharmaceuticals, a clinical-stage biopharmaceutical company. From 2005 to 2017, he was also its President. He joined Sunesis in 2001 and had previously served as the company’s Chief Business Officer and Chief Financial Officer. Prior to that, Mr Swisher held a range of senior management roles, including Senior Vice president of Sales and Marketing at ALZA Corporation, a pharmaceutical and medical systems company, from 1992 to 2001. Mr Swisher has served as Chairman of the Board of Cerus Corporation, a publicly traded biopharmaceutical company, since 2013. Mr Swisher received his BA from Yale University and an MBA from the Stanford Graduate School of Business. Mr Swisher brings to our Board experience in life science industry sales, operations, and finance.